MADISON — Boone County Circuit Judge William Thompson spoke on Jan. 31 in Washington, D.C., at the Office of National Drug Control Policy’s launch of the Rural Community Action Guide.
Prior to the engagement, Thompson spoke about what it means to be able to share his experience with attendees.
“Of course, it is a tremendous honor,” he said. “My hope is that I can share what I have learned in my experiences and, in turn, bring something back to Boone County as well.”
Thompson said he hoped to encapsulate the successes of drug court in Boone County and West Virginia as a whole during his speech.
It wasn’t be the judge’s first trip to the White House. In 2018, Thompson’s drug court was honored as an example of success in Washington, D.C., as Jim Carroll, deputy director of the White House Office of National Drug Control Policy, announced a two-year grant valued at $4 million for the National Association of Drug Court Professionals to provide training and technical assistance to drug courts across the Nation.
Carroll, along with White House Senior Counselor Kellyanne Conway, and the U.S. Surgeon General Dr. Jerome Adams, held a roundtable discussion at the White House with the NADCP leadership, drug court judges, and drug court graduates.
In October, The Boone County Courthouse played host to the announcement of Family Treatment Court. Thompson, who researched the initiative extensively while campaigning publicly for the opportunity to implement it in Boone County, spoke to the CVN then about what he feels will bring more positive results.
“We’re obviously suffering quite a bit with the drug epidemic and through that, our children are suffering,” he said after the event. “We do have some of the infrastructure in place with our drug court and I feel this is a good opportunity for us to get the program started in this state.”
According to its web site, The Office of National Drug Control Policy (ONDCP) works to reduce drug use and its consequences by leading and coordinating the development, implementation and assessment of U.S. drug policy.